Lohiya and Katti developed EGFR/HER2 aptamer-conjugated, DOX-loaded, chitosan-coated mesoporous silica nanoparticles (MSNs) for active targeting of EGFR- and HER2-overexpressing breast cancer cells.83 The developed targeted MSNs exhibited higher uptake and cytotoxicity against triple-negative and HER2-positive breast cancer cells compared to non-targeted MSNs. This evidence concerns the gene ERBB2 and breast cancer.